Login to Your Account

Washington Roundup

Ahead of Adcom, the FDA Questions Serada's Efficacy

By Mari Serebrov
Washington Editor

Friday, March 1, 2013
Depomed Inc.'s Serada could become the first approved nonhormonal therapy for menopausal hot flashes, but its advisory committee debut Monday doesn't look like it's going to be a walk in the park.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription